Brief: Izervay® (Avacincaptad Pegol Intravitreal Solution) Demonstrated Increased Probability Of Maintaining Driving Eligibility In Geographic Atrophy Patients
12/05/2026 14:41
May 12 (Reuters) - Astellas Pharma Inc 4503.T: IZERVAY® (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) DEMONSTRATED INCREASED PROBABILITY OF MAINTAINING DRIVING ELIGIBILITY IN GEOGRAPHIC ATROPHY PATIENTS ASTELLAS PHARMA INC - AT 24 MONTHS, IZERVAY SHOWS 41% RELATIVE RISK REDUCTION VERSUS SHAM FOR LOSS OF DRIVING ELIGIBILITY ASTELLAS PHARMA INC - GATHER2 DATA SHOW IZERVAY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS Source text: ID:nPndMLj6a Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn